We build precision treatments for depression and anxiety by combining novel therapeutics with data-driven patient insights. Instead of trial-and-error prescribing, our approach helps match patients to the right treatment faster, improving outcomes and reducing time to relief.

DermaLabs blends dermatologist-led science with community-powered research. Using decentralized trials, AI imaging, and SKIN token incentives, we turn everyday skincare into measurable evidence. Together, we build transparent, inclusive, and accountable pathways for discovering and validating what truly works for your skin.

GoCART is engineering logic-gated CAR-T cell therapies that activate only when sensing multiple cancer antigens, designed to abolish "on-target, off-tumor" toxicity.

We are developing a new gene therapy to help our canine companions stay stronger, move more comfortably, and enjoy healthier lives as they age. By supporting muscle growth, easing pain, and calming inflammation linked to arthritis, our follistatin therapy aims to improve everyday mobility and overall wellbeing.

As we age, our bodies accumulate senescent, or “zombie", cells which are highly damaged, yet refuse to die. They disrupt tissue homeostasis, are toxic to neighboring cells and are associated with numerous age-related diseases. This project will utilize CRISPR gene-editing technology to find genes that are essential for keeping senescent cells alive, thus providing new drug targets to selectively eliminate them.

We’re building a safe, affordable, and ethically sourced ibogaine therapy for PTSD—using synthetic production, personalized protocols, and transparent governance to make effective treatment accessible worldwide.

PeptAI is an autonomous AI agent that discovers new peptide drug candidates. It designs peptides computationally, then pushes them through an 8-gate validation pipeline. Every result is published on-chain (blockchain) so anyone can verify the science. Once a candidate passes validation, it's sent to the wet-lab for synthesis and binding assays. PeptAI is receptor agnostic, however first programmes target GLP1R, KISS1R, OX2R and several other GPCRs.

This project will design a new RNA therapeutic that nudges the longevity-linked FOXO3 gene into its health-promoting form to halt the tissue breakdown behind degenerative disc disease—opening a precise, scalable route to drugs that extend healthspan.

Relieva is the first proprietary cannabis and hemp derived pre-roll blend designed for pain relief.

The galectin-3 Inhibitors project tests a small molecule under development for peripheral indications for treating neuroinflammation in an Alzheimer’s mouse model. By blocking galectin-3, it aims to reduce brain inflammation, with potential in other neurodegenerative diseases. Galectin-3 is involved in neuroinflammation, thereby the inhibitor has a potential to be used in multiple neurodegenerative diseases.

Accelerating a cure for 100M Long COVID patients. By incentivizing scientists, patients and supporters to collaborate and share data, we’re creating an open marketplace for rapid R&D and commercialization of new treatments for Long COVID. Our first treatment launches January 2025.

Cerebrum DAO is building the world’s largest engaged community focused on enabling scientific breakthroughs that prevent the onset of neurodegeneration and extend our healthy brain years.